Aspire Biopharma Holdings, Inc.
$0.26
▲
0.99%
2026-04-21 05:24:01
aspirebiolabs.com
NCM: ASBP
Explore Aspire Biopharma Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.36 M
Current Price
$0.26
52W High / Low
$35 / $0.22
Stock P/E
—
Book Value
$-1.8
Dividend Yield
—
ROCE
308.11%
ROE
618.48%
Face Value
—
EPS
$-16.38
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1
Debt / Equity
-0.81
Current Ratio
0.17
Quick Ratio
0.14
Forward P/E
—
Price / Sales
858.69
Enterprise Value
$9.5 M
EV / EBITDA
—
EV / Revenue
1,531.27
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arrowhead Pharmaceuticals, Inc. | $71.64 | 46.54 | $10.05 B | — | 8.27% | 75.5% | $76.76 / $10.92 | $4.14 |
| 2. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 3. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 4. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 5. | Coya Therapeutics, Inc. | $4.99 | — | $112.13 M | — | -51.17% | -51.39% | $7.75 / $3.71 | $2.06 |
| 6. | Tenax Therapeutics, Inc. | $14.1 | — | $247.99 M | — | -58.09% | -55.64% | $18.38 / $4.63 | $2.29 |
| 7. | Kalaris Therapeutics, Inc. | $6.6 | — | $132.49 M | — | -41.2% | -3.08% | $11.88 / $2.14 | $3.44 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.85 M | -1.15 M | -0.8 M | -15.56 M | -2.52 M | — |
| Net Profit | -4.71 M | -1.85 M | -1.98 M | -15.94 M | -11.97 M | — |
| EPS in Rs | -0.94 | -0.37 | -0.39 | -3.17 | -2.38 | -0.19 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.01 M | 0 M | 0 M | 0 M |
| Operating Profit | -19.35 M | -1.21 M | -1.34 M | -0.6 M |
| Net Profit | -24.48 M | -1.31 M | 4.46 M | -0.6 M |
| EPS in Rs | -4.87 | -0.26 | 0.89 | -0.12 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.31 M | 0.15 M | 0.05 M | 0.02 M |
| Total Liabilities | 7.69 M | 1.69 M | 0.53 M | 0.15 M |
| Equity | -6.38 M | -1.54 M | -0.49 M | -0.13 M |
| Current Assets | 1.31 M | 0.15 M | 0.05 M | 0.02 M |
| Current Liabilities | 7.59 M | 1.69 M | 0.53 M | 0.15 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.92 M | -0.27 M | 0.01 M | -0.14 M |
| Investing CF | — | 0 M | 0 M | -4.9 M |
| Financing CF | 5.92 M | 0.26 M | 0 M | 4.85 M |
| Free CF | -4.92 M | -0.27 M | 0.01 M | -5.04 M |
| Capex | — | — | -0.08 M | -4.9 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -1768.95% | -129.34% | 847.61% | — |
| Profit Margin % | -394725.06% | — | — | — |
| Operating Margin % | -312016.95% | — | — | — |
| Gross Margin % | -1.87% | — | — | — |
| EBITDA Margin % | -257168.22% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-16 | 1:0.025 |